Daniela Kantárová, Milan Buc, Dana Prídavková, Ivana Ságová, Mojmír Vrlík, Marián Mokáň
Autoimmune type 1 diabetes mellitus (DM1A) is organ-specific autoimmune disease with increasing prevalence all over the world. Autoimmune aetiology of the disease is well known but until now only the substitution of exogenous insulin has been used in the therapy. The improving of immunosuppressive medication is one of the possibilities for causal treatment of this disease. Especially application of modified monoclonal antibodies against CD3 membrane molecule of T cells shows a very promising effect. It improves metabolic compensation, therapeutic doses of exogenous insulin could be decreased and development of chronic diseases is reduced.